SCIENTIFIC AGENDA







Dr. H. Malvi President Bhopal Haematology Society

Organising Secretary

Dr. Shailesh Lunawat Dr. Abhishek Sharma **Program Convener**

Dr. TP Sahoo Director Silver Line Hospital, Bhopal



Contact us : Rishabh Joshi +91 9773864216





TIME	TOPICS	SPEAKERS
09:00- 10:00 AM	Registration & Networking	
10:00- 10:05 AM	Setting the Context	Dr. TP Sahoo, Bhopal
10:05- 10:25 AM	Antibody Drug Conjugates: Linkers, Payloads and Future	Dr. Purvish Parikh, Jaipur
	Session 1 : Genito urinary cancer	
	Chairperson	Dr. OP Singh,Bhopal Dr. Chirag Desai, Ahmedabad Dr Arvind Joshi Bhopal
10:25- 10:40 AM	Adjuvant Therapy in Urotheial Malignancy and Renal Cancer - Why one IO works and others don't?	Dr. Bharat Vaswani, Hyderabad
10:40- 11:10 AM	Panel Discussion: Metastatic RCC	
	Moderator:	Dr Amish Vora , Delhi
	Panelist	Dr. Amit Joshi, Mumbai
		Dr Soumya Panda, Bhubaneshwar
		Dr. Vijay Bhargava, Bhopal
		Dr. Roshni Pande, Jabalpur
		Dr. Stalin Chowdhary Bala,Visakhapatnam Dr. Vamshi Krishna, Hyderabad
		Dr. Jacob George, Goa
	Academic Partner: Adley	Disteob George, oou
11:10- 11:40 AM	Panel Discussion :	
	Castrate Resistant Prostrate Cancer (CRPC) Second Line and Beyond	
	Moderator:	Dr Senthil Rajjapa, Hyderabad
	Panelists:	Dr. Vineet Talwar, Delhi
		Dr Amit Joshi Mumbai
		Dr. Ranjit Sahoo, Delhi
		Dr. Vikas Talreja, Kanpur
		Dr. Ashish Gupta, Jabalpur Dr. Praveen Paliwal' Bhopal
		Dr.Roshni Pande, Jabalpur





TIME	TOPICS	SPEAKERS
	Moderator:	Dr. Vineet Talwar, Delhi
11:40- 12:00 PM	Debate: Concurrent Induction ICI with Chemotherapy followed by Maintenance ICI is the way forward in Advanced Cancer Urinary Bladder	
	Yes No	Dr. Ranjit Sahoo, Delhi Dr. Amol Akhade, Mumbai
12:00- 12:05 PM	Expert Opinion	Dr. Vineet Talwar, Delhi
	Academic Partner: BMS	
12:05- 12:45 PM	Panel Discussion: Improving Survival and Quality of Life in frontline advanced RCC with CTLA-4 & PD-1 inhibition	
	Moderator:	Dr. Vikas Asati, Indore
	Panelists:	Dr. Akash Tiwari, Indore Dr. Satvik Khaddar, Indore Dr. Amit Joshi, Mumbai Dr. Vikas Talreja, Kanpur
	Session 2 : Lung Cancer	
	Chairperson	Dr. Lokendra Dave, Bhopal Dr Prakash Chitalkar, Indore Dr. Manish Gupta, Bhopal
12:45- 01:15 PM	Panel Discussion: Optimizing Immune check point inhibitors in Early Lung Cancer Moderator: Panelists:	Dr. Ullas Batra, Delhi Dr. Nitesh Rohatgi, Delhi Dr. Bharat Vaswani, Hyderabad Dr. Jacob George, Goa Dr. Kinjal jani RO, Ahemdabad Dr. Satvik Khaddar, Indore Dr. Krushna Chaudhary, Indore Dr. Hemant Dadhich, Kota Dr. Stalin Chowdhary Bala, Visakhapatnam





TIME	TOPICS	SPEAKERS
01:15- 01:30 PM	Academic Partner: AstraZeneca Optimizing treatment decision in unresectable stage IIINSCLC_ A Case study	Dr. S P Shrivastava, Indore
01:30- 01:50 PM	Moderator: Debate: Is the time ripe to switch all patients with EGFR – positive (Exon 19 and 21) mutations to concurrent TKI and CT in Advanced NSCLC Yes	Dr. Bhavesh Parekh, Ahmedabad Dr. Kumar Prabhash, Mumbai
01:50- 01:55 PM	No Expert Opinion	Dr. Senthil Rajappa , Hyderabad Dr. Bhavesh Parekh, Ahmedabad
01:55- 02:15 PM	Immunotherapy : Indian Experience	Dr Kumar Prabhash, Mumbai
02:15 - 03:00 PM	Lunch	
	Session 3: Breast Cancer	
	Chairperson	Dr Vivek Tiwari, Bhopal Dr. Rajeev Sharda Bhopal Dr. Rahul Agarwal Bhopal
03:00 - 03:15 PM	How do I treat Early TNBC	Dr. Nitesh Rohtagi, Delhi
03:15- 03:45 PM	Panel Discussion: Optimising ImmunotherapyProtocols in TNBC (Both Neo Adjuvant and Metastatic)	
	Moderator: Panelists:	Dr. Ashish Singh, Vellore Dr. Ullas Batra, Delhi Dr. Amol Akhade, Mumbai Dr. Nikhil Ghadyalpatil, Hyderabad Dr. Vamshi Krishna, Hyderabad Dr. Ghanshyam Biswas, Bhubneshwar Dr. Atul Batra, Delhi Dr. Akansha Choudhary, Bhopal





TIME	TOPICS	SPEAKERS
03:45 - 04:05 PM	Newer ADC's for HER2 Positive Breast Cancer	Dr. Chetan Deshmukh, Pune
	Academic Partner: AstraZeneca	
04:05 - 04:20 PM	Role of Trastuzumab Deruxtecan in HER2 expressing tumours	Dr. Praveen Paliwal, Bhopal
	Academic Partner: Zydus	
04:20 - 04:35 PM	Panel Discussion- Unraveling The Path of HER2+ breast cancer in next 2 years Moderator: Panelist:	Dr. TP Sahoo, Bhopal Dr. Praveen Paliwal, Bhopal Dr. S P Shrivastava, Indore Dr. Akash Tiwari, Indore Dr. Vikas Asati, Indore Dr. Vinay K. Sharma, Bhopal
	Academic Partner: Eli Lilly	
04:35 - 04:55 PM	Moderator:	Dr Govind Babu, Bengaluru
	Debate: Adjuvant CDK 4/6 Inhibitors : Are The Way Ahead in Early Breast Cancer Yes No	Dr. Atul Batra, Delhi Dr. Bhavesh Parekh, Ahmedabad
04:55-05:00 PM	Expert Opinion	Dr. Govind Babu, Bengaluru
05:00- 05:30 PM	Panel Discussion:Hormone Positive MBC	
	 A. Optimising the sequencing of therapies in 2025 (Assuming all FDA approved drugs are available for use) B. Which cdk 4/6 Inhibitor for upfront Use C. Importance of SONIA trial in 2024 	
	Moderator:	Dr. Ankur Bahl, Delhi
	Panelists:	Dr. Biswajit Dubhashi, Pondicherry Dr. Chetan Deshmukh, Pune Dr. Vikas Asati, Indore Dr. S P Shrivastava, Indore Dr. Vikas Talreja, Kanpur Dr. Anbarasan Sekar, Mumbai Dr. Ashish Singh, Vellore





TIME	TOPICS	SPEAKERS
05:30 - 05:45 PM	Tea Break	
	Session 4: Dual Immune checkpoint inhibitor	
	Chairperson	Dr. Govind Babu, Bengaluru Dr. Bhavesh Parekh, Ahmedabad Dr. Saikat Das Bhopal
05:45 - 06:05 PM	Dual Immune checkpoint inhibitors: Does benefit outweigh the cost and toxicity ?	Dr. Nikhil Gadyalpatil, Hyderabad
06:05 - 06:35 PM	Panel Discussion: Dual Immunotherapy	
	Moderator:	Dr. Chirag Desai, Ahmedabad
	Panelists:	Dr. Ankur Bahl, Delhi Dr. Atul Batra,Delhi Dr. Rajat Bajaj, Delhi Dr. Shaunak Valame, Bhopal Dr. Biswajit Dubhashi, Pondicherry Dr. Prateek Tiwari, Bhopal Dr. Shashank Bansal, Bhopal
	Chairperson	Dr. Hemant Dadhich, Kota Dr. Ravi Jaiswal, Raipur
	Spotlight session	
	Academic Partner: Zydus	
06:35 - 06:50 PM	Liquid is solid - in the management of advanced Lung Cancer	Dr. Akash Tiwari, Indore
	Academic Partner: Roche	
06:50 - 07:05 PM	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-cell Lymphoma	Dr. Rakesh Taran, Indore





TIME	TOPICS	SPEAKERS
07:05- 07:15 PM	Academic Partner: Roche Atezolizumab plus chemotherapy and bevacizumab in 1L non-squamous mNSCLC- IMpower 150	Dr. S P Shrivastava ,Indore
07:15- 07:30 PM	Academic Partner: Dr. Reddy's A Review on Targeting HER2-positive Breast Cancer with Dual HER2 Block	Dr. Rajesh Patidar, Indore
	Hard Talks	
08:30- 08:50 PM	How will AI change our lives in 2024	Dr. Purvish Parikh, Jaipur
08:50- 09:40 PM	Death and Medical Negligence - IPC 304A vs Bharatiya Nyaya Sanhita 2023 section 108.	Dr. Purvish Parikh, Jaipur
9:40 PM Onwards	Dinner	





TIME	TOPICS	SPEAKERS
09:00- 09:30 AM	Registration & Networking	
9:30 - 09:45 AM	Welcome & Introduction	Dr. TP Sahoo, Bhopal
	Chairperson	Dr. Rakesh Taran, Indore
	Academic Partner: Eli Lilly	
09:45- 10:00 AM	Latest disclosures of Abemaciclib in HR+ HER2- High risk Early breast cancer (EBC)	Dr. Vikas Talreja, Kanpur
	Session 1: Hepatobiliary and GI cancer	
	Chairperson	Dr. Sanjay Kumar, Bhopal Dr. Sandesh Sharma, Bhopal Dr. Chetan Deshmukh, Pune
10:00- 10:20 AM	Immunotherapy For CRC	Dr. Viraj Lavingia, Ahemdabad
10:20 - 10:50 AM	Panel Discussion: Advanced Inoperable Hepatocellular Carcinoma Choosing first line therapies in 2024	
	Moderator:	Dr. Vamshi Krishna, Hyderabad
	Panelists:	Dr. Viraj Lavingia, Ahemdabad Dr. Anant Ramaswamy, Mumbai Dr. Arun Gupta, Delhi Dr Vijay Bhaskar, Bengaluru Dr. Anbarasan Sekar, Mumbai Dr. Nilesh Lokeshwar, Mumbai Dr. Sunit Lokwani, Indore Dr. Ravi Jaiswal, Raipur
	Moderator:	Dr Atul sharma, Delhi
10:50 - 11:10 AM	Debate - Perioperative Chemo vs CTRT in Gastric Cancer For FLOT Protocol : For CROSS Protocol :	Dr. Amol Patel, Lucknow Dr. Krupa Shankar, Coimbatore





TIME	TOPICS	SPEAKERS
11:10 - 11:15 AM	Expert Opinion	Dr Atul sharma, Delhi
11:15 - 11:45 PM	Panel Discussion: Sequencing Therapies for advanced Stomach and GE Junction Cancers	
	Moderator:	Dr. Anant Ramaswamy, Mumbai
	Panelists:	Dr. Atul Sharma , Max Delhi Dr. Randeep Singh, Gurugram Dr. Sandeep Batra, Gurugram Dr. Sumit Goyal, Delhi Dr. Akash Tiwari, Indore Dr. Krupa Shankar, Coimbatore
11:45 - 12:00 PM	Is the evidence strong enough to recommend peri-operative immune checkpoint inhibitors in gastric and GE Junction cancer ?	Dr. Amish Vora , Delhi
	Session 2: Gynecological cancer	
	Chairperson	Dr Sudeep Gupta, Mumbai Dr. Hameed Ghori, Bhopal Dr. Gaurav Gupta Bhopal
12:00 - 12:15 PM	Parp Inhibitors In Ovarian Cancer in present Scenario	Dr. Vaibhav Chaudhary Mumbai
12:15 - 12:35 PM	Bio markers in Operable Endometrial Cancer and its relevance in clinical practice	Dr Vijay Agarwal , Bengaluru





TIME	TOPICS	SPEAKERS
12:35 - 01:05 PM	Panel Discussion: Advanced Cancer Endometrium (Sequencing Of Available Treatment Options)	
	Moderator:	Dr. Shyam Aggarwal, Delhi
	Panelists:	Dr Chetan Deshmukh, Pune Dr Chirag Desai, Ahmedabad Dr. Rajat Bajaj , Delhi Dr Amol Patel, Lucknow Dr Soumya Panda, Bhubaneshwar Dr. Nilesh Lokeshwar, Mumbai Dr. Vijay Agarwal , Bengaluru
	Moderator:	Dr Ghanshyam Biswas,
01:05 - 01:25 PM	Debate: Cancer Cervix - NACT is the way forward before initiating Concurrent Radical Chemoradiotherapy	Bhubaneswar
	Yes: No: Will Speak in Favour of Concurrent ICI	Dr. Randeep Singh, Delhi Dr. Rajat Bajaj , Delhi
01:25 - 01:30 PM	Expert Opinion	Dr Ghanshyam Biswas, Bhubaneswar
01:30 - 01:40 PM	Expert Comments	Dr Sudeep Gupta, Mumbai
	Academic Partner: AstraZeneca	
01:40 - 01:55 PM	Recent updates in advanced endometrial cancer	Dr. Chirag Desai, Ahemdabad
01:55 PM Onwards	Closing Remaks followed by Lunch	Dr. TP Sahoo, Bhopal





Academic Partners



